abstract |
The present invention relates to a pharmaceutical composition, particularly a pharmaceutical composition comprising an IgG:TGFβRII (such as an anti-PD-L1:TGFp-inhibiting) fusion protein. The present invention also relates inter alia to a method of manufacturing the composition, to a kit including the composition, to a package including the composition, to a method of manufacturing the package, and to methods of treatment using the composition and/or package, especially cancer treatments. |